Report tracks industry progress on drug resistance

Publication

CIDRAP

By

Chris Dall

A report today from an international association of life sciences companies suggests that the private sector is making progress in meeting its commitment to help solve the antimicrobial resistance (AMR) crisis, but much work remains.

The progress report from the AMR Industry Alliance, a collection of more than 100 companies and trade associations representing the pharmaceutical, biotechnology, generics, and diagnostics industries, indicates that industry investment in AMR-related research and development is significant and has resulted in a handful of new products in development, including antibiotics, vaccine candidates, and diagnostic products.

More News

News

A Decade of Action on AMR: Reflections and Path to 2029

In the news

WAAW Webinar 2025

News

AMR Industry Alliance Releases “Principles for Pooled Procurement of AMR Products”